Skip to main content
LQDA
NASDAQ Life Sciences

Director-affiliated entity files intent to sell $15.9M in Liquidia Corp stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$52.56
Mkt Cap
$4.682B
52W Low
$11.85
52W High
$53.93
52W Position info
344% above low
Off High info
2.5% below high
Rel. Volume info
4.7× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85 on elevated volume (4.7× avg).

Summary

A director-affiliated entity, Canaan VIII LP, plans to sell $15.9 million of Liquidia Corp stock, adding to recent insider selling activity while the stock trades near its 52-week high.


Key Events · Ownership and Investor Activity · LQDA

  • Intent to Sell Significant Stake

    Canaan VIII LP, an entity with a director relationship, filed a Form 144 to sell 318,893 shares of common stock, valued at approximately $15.9 million.

  • Follows Recent Insider Selling

    This proposed sale by Canaan VIII LP follows previous sales of 70,234 shares for $2.53 million by the same entity within the last three months, indicating a pattern of disposition.

  • Stock Trading Near 52-Week High

    The filing occurs while Liquidia Corp's stock is trading near its 52-week high of $53.93, potentially influencing the timing of the sale.


Analysis · LQDA · Life Sciences

Canaan VIII LP, an entity with a director relationship to Liquidia Corp, has filed a Form 144 indicating its intent to sell approximately $15.9 million worth of common stock. This proposed sale represents a notable portion of the company's outstanding shares and follows previous sales by the same entity in the past three months, suggesting a continued reduction in its holdings. The stock is currently trading near its 52-week high, which could be a factor in the timing of this disposition.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $52.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $11.85 to $53.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $43.10 info
Change: +$3.60 (+9%) info
Market Cap: $3.982B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $43.10 info
Change: +$11.34 (+36%) info
Market Cap: $3.982B info
LQDA
Oct 02, 2026, 11:47 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.77
Real-time Price: $43.10 info
Change: +$15.33 (+55%) info
Market Cap: $3.982B info
LQDA
Oct 01, 2026, 12:03 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $26.22
Real-time Price: $43.10 info
Change: +$16.88 (+64%) info
Market Cap: $3.982B info
LQDA
Sep 30, 2026, 1:20 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $53.22
Real-time Price: $43.10 info
Change: -$10.12 (-19%) info
Market Cap: $3.982B info